Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature
Pharmacopsychiatry · 01.05.2024 · 57 (03) · 104-114
DOI: 10.1055/a-2256-0098 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacopsychiatry, erschienen am 01.05.2024. Verfasst von Kirsten R Müller-Vahl. Beteiligte Einrichtung: Clinic of Psychiatry, Socialpsychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Cannabinoids, Mental Disorders. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Although an increasing number of patients suffering from mental illnesses self-medicate with cannabis, current knowledge about the efficacy and safety of cannabis-based medicine in psychiatry is still extremely limited. So far, no cannabis-based finished product has been approved for the treatment of a mental illness. There is increasing evidence that cannabinoids may improve symptoms in autism spectrum disorder (ASD), Tourette syndrome (TS), anxiety disorders, and post-traumatic stress disorder (PTSD). According to surveys, patients often use cannabinoids to improve mood, sleep, and symptoms of attention deficit/hyperactivity disorder (ADHD). There is evidence suggesting that tetrahydrocannabinol (THC) and THC-containing cannabis extracts, such as nabiximols, can be used as substitutes in patients with cannabis use disorder. Preliminary evidence also suggests an involvement of the endocannabinoid system (ECS) in the pathophysiology of TS, ADHD, and PTSD. Since the ECS is the most important neuromodulatory system in the brain, it possibly induces beneficial effects of cannabinoids by alterations in other neurotransmitter systems. Finally, the ECS is an important stress management system. Thus, cannabinoids may improve symptoms in patients with mental illnesses by reducing stress. Practically, cannabis-based treatment in patients with psychiatric disorders does not differ from other indications. The starting dose of THC-containing products should be low (1–2.5 mg THC/day), and the dose should be up-titrated slowly (by 1–2.5 mg every 3–5 days). The average daily dose is 10–20 mg THC. In contrast, cannabidiol (CBD) is mainly used in high doses>400 mg/day.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinic of Psychiatry, Socialpsychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany.
Zitieren
APA
Müller-Vahl, K. R. (2024). Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature. Pharmacopsychiatry, 57(03), 104-114. https://doi.org/10.1055/a-2256-0098
Vancouver
Müller-Vahl KR. Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature. Pharmacopsychiatry. 2024;57(03):104-114. doi:10.1055/a-2256-0098
BibTeX
@article{MllerVahl2024,
author = {Müller-Vahl, Kirsten R},
title = {Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature},
journal = {Pharmacopsychiatry},
year = {2024},
volume = {57},
number = {03},
pages = {104--114},
doi = {10.1055/a-2256-0098}
}
EUVIMED